1. CMND completed patient enrollment for Phase I/IIa trial of CMND-100. 2. First cohort showed top-line safety and efficacy data for CMND-100. 3. Second cohort reacts positively, highlighting clinical interest in CMND-100. 4. Dosing for the second cohort begins soon; topline results expected shortly. 5. Clearmind focuses on innovative treatments for Alcohol Use Disorder.
FAQ
Why Bullish?
Successful enrollment and positive initial results indicate strong potential for CMND-100. Companies that report progress in clinical trials often see stock price appreciation, as evidenced by Biogen's stock increases after positive trial news.
How important is it?
The significant progress in clinical trials directly boosts investor sentiment and the company’s valuation. Rapid patient enrollment reflects operational effectiveness, enhancing confidence in CMND-100's development.
Why Short Term?
Topline results anticipated in coming months will likely influence stock price quickly. Previous examples show rapid market reactions to clinical trial updates, such as Moderna's spikes post-results disclosure.
Clearmind Medicine Completes Second Cohort Enrollment in Phase I/IIa Trial for CMND-100
On December 16, 2025, Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company specializing in novel neuroplastogen-derived therapeutics, announced the successful completion of patient enrollment for the second cohort in its FDA-approved Phase I/IIa clinical trial. This trial is evaluating CMND-100, Clearmind’s proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD).
Cohort Details and Rapid Recruitment
The second cohort consists of six patients, recruited swiftly across three esteemed clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. This milestone follows the completion of the first cohort, which showed promising top-line safety and efficacy data, including a favorable safety profile and early indications of reduced cravings and withdrawal symptoms.
Significance of the Trial
The rapid enrollment in this second cohort underscores the operational excellence of the collaborating clinical centers and their commitment to advancing innovative treatments for AUD—an affliction impacting millions globally with limited effective solutions. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, expressed enthusiasm regarding this progress, stating, “We are thrilled with the accelerated pace of enrollment for our second cohort, which reflects the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment.”
About the Phase I/IIa Trial
The multinational Phase I/IIa trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary effectiveness of CMND-100 in patients diagnosed with moderate to severe AUD. Dosing for the second cohort is expected to commence shortly, with topline results anticipated in the coming months.
About Clearmind Medicine Inc.
Clearmind is committed to developing novel psychedelic-derived therapeutics to address widespread and underserved health issues, including AUD. The company's strategy focuses on researching and commercializing psychedelic-based compounds as regulated medicines, foods, or supplements. Currently, Clearmind's intellectual property portfolio contains nineteen patent families, comprising 31 granted patents, and the company aims to expand its portfolio further.
Trading Information
Shares of Clearmind are available for trading on Nasdaq under the symbol CMND and on the Frankfurt Stock Exchange under the symbol “CWY0.” For additional details, visit Clearmind Medicine's website or reach out to their Investor Relations team at invest@clearmindmedicine.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. Such statements include discussions of advancing AUD treatments, expectations of interest in CMND-100, and the potential for the drug to address the root causes of addiction. Actual results may vary materially from these expectations due to numerous risks and uncertainties.